发明名称 |
PHARMACEUTICAL FORMULATIONS FOR THE CONTROLLED RELEASE OF 4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL) QUINAZOLINE |
摘要 |
The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37 DEG C. Formulations according to the invention are suitable for the treatment of BPH.
|
申请公布号 |
WO03032956(A1) |
申请公布日期 |
2003.04.24 |
申请号 |
WO2002IB04040 |
申请日期 |
2002.09.30 |
申请人 |
PFIZER LIMITED;DAVIS, JOHN, DOUGLAS;HUMPHREY, MICHAEL, JOHN;MACRAE, ROSS, JAMES;SMITH, JANET, SARAH;PFIZER INC. |
发明人 |
DAVIS, JOHN, DOUGLAS;HUMPHREY, MICHAEL, JOHN;MACRAE, ROSS, JAMES;SMITH, JANET, SARAH |
分类号 |
A61K9/00;A61K9/20;A61K9/22;A61K9/50;A61K9/52;A61K31/517;A61K47/02;A61K47/12;A61K47/18;A61K47/22;A61K47/26;A61K47/38;A61P13/08;(IPC1-7):A61K9/22 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|